• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

METHOTREXATE Drug Record

  • Summary
  • Interactions
  • Claims
  • METHOTREXATE chembl:CHEMBL34259 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    MAXTREX
    RASUVO
    EMTEXATE PF
    METOJECT
    R-METHOTREXATE
    MEXATE-AQ
    ABITREXATE
    R-9985
    METHYLAMINOPTERIN
    NSC-740
    OTREXUP PFS
    TCMDC-125488
    TCMDC-123832
    AMETHOPTERIN
    EMT-25299
    RHEUMATREX
    OTREXUP
    TCMDC-125858
    EMTEXATE HIGH-POT
    MEXATE
    EBETREX
    METHOTREXATE
    TREXALL
    ZLATAL
    FOLEX
    CL-14377
    METOTREXATO
    RASUVO®
    MTX
    ABITREXATE®
    4-AMINO-10-METHYLFOLIC ACID
    N-[4-[[(2,4-DIAMINO-6-PTERIDINYL)METHYL]METHYLAMINO]BENZOYL]-L-GLUTAMIC ACID
    METHOTREXATUM
    4-AMINO-N(10)-METHYLPTEROYLGLUTAMIC ACID
    METHOTREXAT
    MÉTHOTREXATE
    chemidplus:59-05-2
    chembl:CHEMBL34259
    pubchem.compound:126941
    drugbank:00563
    rxcui:6851

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications DMARD
    (8 More Sources)

    Publications:

    Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
    Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer
    Allegra et al., 1985, Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates., Proc. Natl. Acad. Sci. U.S.A.
    López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J
    Kurzawski M et al., 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients., Pharmacogenomics
    Lima A et al., 2016, Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome., Pharmacogenomics
    Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
    Muralidharan N et al., 2016, ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis., Pharmacogenomics
    Salazar J et al., 2014, Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?, Pharmacogenomics
    Iannaccone CK et al., 2011, Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study., Rheumatology (Oxford)
    James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
    Wessels JA et al., 2006, Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis., Arthritis Rheum
    Dervieux T et al., 2004, Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis., Arthritis Rheum
    Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet
    Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood
    Kodidela S et al., 2015, Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia., Eur J Clin Pharmacol
    Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J
    Salazar J et al., 2012, Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia., Pharmacogenomics J
    Sharma S et al., 2009, Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians., Pharmacogenet Genomics
    Al-Shakfa F et al., 2009, DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia., Clin Cancer Res
    Ongaro A et al., 2009, Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival., Haematologica
    Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry
    Hänggi et al., 1976, Altered regulation of the rate of synthesis of dihydrofolate reductase in methotrexate-resistant hamster cells., J. Biol. Chem.
    Wani et al., 1994, Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells., Cancer Res.
    Kaufman et al., 1981, Amplification and loss of dihydrofolate reductase genes in a Chinese hamster ovary cell line., Mol. Cell. Biol.
    Domin et al., 1983, Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy., Cancer Res.
    Thompson et al., 1992, Assay for expression of methotrexate-resistant dihydrofolate reductase activity in the presence of drug-sensitive enzyme., J Pharmacol Toxicol Methods
    Selassie et al., 1982, A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate., J. Med. Chem.
    Cavalcanti et al., 1992, Simultaneous changes in various mechanisms that mediate the cell incorporation of folate compounds account for low levels of resistance to methotrexate., Cell Biochem. Funct.
    Serra et al., 2004, Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells., Ann. Oncol.
    Bennett et al., 2006, Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate., Proc. Natl. Acad. Sci. U.S.A.
    Uga et al., 2006, A new mechanism of methotrexate action revealed by target screening with affinity beads., Mol. Pharmacol.
    Al-Rashood et al., 2006, Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs., Bioorg. Med. Chem.
    Totani et al., 2006, High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates., Bioorg. Med. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Assaraf, 2007, Molecular basis of antifolate resistance., Cancer Metastasis Rev.
    Costea I et al., 2006, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia., Haematologica
    Costea et al., 2003, The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia., Pharmacogenetics
    Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood
    Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    den Hoed MA et al., 2015, Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia., Pharmacogenomics J
    Lopez-Lopez E et al., 2013, Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia., Pharmacogenet Genomics
    Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
    Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer
    Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet
    Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.
    Jekic B et al., 2013, Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients., Eur J Clin Pharmacol
    Hayashi H et al., 2009, Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis., J Clin Pharm Ther
    van der Straaten RJ et al., 2007, Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients., Pharmacogenomics
    Garcia-Bournissen F et al., 2007, Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene., Leuk Res
    Dervieux T et al., 2004, Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis., Pharmacogenetics
    Cheng Q et al., 2004, A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells., Pharmacogenetics
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
    Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
    Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids
    Krajinovic M et al., 2005, Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis., Pharmacogenomics J
    Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.
    Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
    Ansari M et al., 2012, Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia., Pharmacogenomics J
    Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol
    Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics
    Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics
    Huang L et al., 2008, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia., Leukemia
    de Jonge R et al., 2005, Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia., Blood
    Yanagimachi M et al., 2013, Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy., Int J Hematol
    Simon N et al., 2013, Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy., Pharmacogenomics J
    Ranganathan P et al., 2008, Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis., J Rheumatol
    Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.
    Chen Y et al., 2017, Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis., Pharmacogenomics
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
    Pohl et al., 2003, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin., J. Clin. Oncol.
    Foell et al., 2004, Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?, Ann. Rheum. Dis.
    Pinto et al., 1996, Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells., Clin. Cancer Res.
    Lecomte et al., 2000, Maurotoxin and the Kv1.1 channel: voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys31-Cys34., J. Pept. Res.
    Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
    Dervieux T et al., 2009, Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis., Pharmacogenet Genomics
    Imanishi et al., 2007, Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma., J. Hum. Genet.
    López-Rodríguez R et al., 2018, Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis., Sci Rep
    Lima A et al., 2015, Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci
    Warren RB et al., 2008, Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis., J Invest Dermatol
    Yang JJ et al., 2009, Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia., JAMA
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Plant D et al., 2012, A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register., Pharmacogenomics J
    Hider SL et al., 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX., Rheumatology (Oxford)
    Xian et al., 2000, Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis., Br. J. Cancer
    Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol
    Liu SG et al., 2017, Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia., Oncotarget
    Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
    Goričar K et al., 2014, Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma., Pharmacogenet Genomics
    Csordas K et al., 2014, Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia., Br J Haematol
    Ramsey LB et al., 2013, Genome-wide study of methotrexate clearance replicates SLCO1B1., Blood
    Treviño LR et al., 2009, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects., J Clin Oncol
    Tirona RG et al., 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans., J Biol Chem
    Chen et al., 2006, Nuclear receptor interactions in methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1)., J. Biochem. Mol. Toxicol.
    Majorczyk E et al., 2014, Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment., BMC Musculoskelet Disord
    Kohli et al., 1990, Expression and amplification of cloned rat liver tyrosine aminotransferase in nonhepatic cells., J. Cell. Physiol.
    Lora et al., 2004, Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells., Eur. J. Biochem.
    Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
    Kooloos WM et al., 2010, Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis., Pharmacogenomics
    Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
    López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.
    Krajinovic M et al., 2005, Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL., Pharmacogenomics
    Baggott et al., 1986, Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide., Biochem. J.
    Stamp LK et al., 2009, Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis., Ann Rheum Dis
    Rizzo R et al., 2006, HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis., Pharmacogenet Genomics
    Barbisan F et al., 2014, Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism., PLoS One
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Morita et al., The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production., Scand. J. Rheumatol.
    Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.
    Yazici et al., 2005, The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment., Arch. Dermatol. Res.
    Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.
    Hall et al., Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells., Int. J. Immunopharmacol.
    Seitz et al., 1996, Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate., J. Rheumatol.
    Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
    Abida et al., 2002, Receptor-dependence of the transcription read-out in a small-molecule three-hybrid system., Chembiochem
    Nakagawa H et al., 2008, Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2., Biochem J
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol
  • METHOTREXATE   ATIC

    Interaction Score: 4.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    3860829 29520081 27885916 27676277 27217051 26799664 25084201 20847201 18322994 16947783 15457444 24284432


    Sources:
    NCI PharmGKB

  • METHOTREXATE   MTRR

    Interaction Score: 2.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29743634 18368069 16013960 15797993


    Sources:
    PharmGKB

  • METHOTREXATE   AMPD1

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29520081 27992285 27217051 20386493 16947783


    Sources:
    PharmGKB

  • METHOTREXATE   SPECC1L

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18539621


    Sources:
    PharmGKB

  • METHOTREXATE   SLAMF1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16882589


    Sources:
    NCI

  • METHOTREXATE   KIR2DS4

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25069714


    Sources:
    PharmGKB

  • METHOTREXATE   NALCN

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19176441


    Sources:
    PharmGKB

  • METHOTREXATE   SLC22A9

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • METHOTREXATE   S100A8

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14722212


    Sources:
    NCI

  • METHOTREXATE   PTPRM

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24583629


    Sources:
    PharmGKB

  • METHOTREXATE   ADORA2A-AS1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27399166


    Sources:
    PharmGKB

  • METHOTREXATE   DHFR

    Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name VIBEX MTX
    Mechanism of Interaction Dihydrofolate reductase inhibitor

    PMIDs:
    26335211 25778468 25084201 21747412 19902562 19861437 19648163 9129 944698 8162600 7346712 6831441 1489988 7057421 1533575 14679136 17130456 16936229 16971132 16647263 11752352 17333344 24284432


    Sources:
    TdgClinicalTrial ChemblInteractions NCI PharmGKB

  • METHOTREXATE   ITPA

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29520081 27217051 26237184 19858780 16947783


    Sources:
    PharmGKB

  • METHOTREXATE   SLC46A1

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21317831


    Sources:
    PharmGKB TTD

  • METHOTREXATE   GGH

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22763757 19827168 17286537 16999998 15564880 15284538


    Sources:
    PharmGKB

  • METHOTREXATE   SHMT1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22838948 20386493 18368069 18322994 15797993


    Sources:
    PharmGKB

  • METHOTREXATE   ARID5B

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24712521


    Sources:
    PharmGKB

  • METHOTREXATE   SLC16A7

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   TNFAIP3

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20921970


    Sources:
    PharmGKB

  • METHOTREXATE   PACSIN2

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22846425


    Sources:
    PharmGKB

  • METHOTREXATE   HLA-G

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19088262 16906016


    Sources:
    PharmGKB

  • METHOTREXATE   IL1RN

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8877917


    Sources:
    NCI

  • METHOTREXATE   SLC22A11

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26086825


    Sources:
    PharmGKB

  • METHOTREXATE   FPGS

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19902562


    Sources:
    PharmGKB

  • METHOTREXATE   FOXP3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28444425


    Sources:
    PharmGKB

  • METHOTREXATE   PYGL

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007406


    Sources:
    PharmGKB

  • METHOTREXATE   ENOSF1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18322994 16130010


    Sources:
    PharmGKB

  • METHOTREXATE   ICAM3

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16215763


    Sources:
    NCI

  • METHOTREXATE   ATP5F1E

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26307125


    Sources:
    PharmGKB

  • METHOTREXATE   SULT2A1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17163485


    Sources:
    NCI

  • METHOTREXATE   KLRD1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26453102


    Sources:
    PharmGKB

  • METHOTREXATE   SOD2

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25330300


    Sources:
    PharmGKB

  • METHOTREXATE   SLCO1A2

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21317831


    Sources:
    PharmGKB

  • METHOTREXATE   S100A12

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15077313


    Sources:
    NCI

  • METHOTREXATE   FOLH1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9816319 22838948


    Sources:
    NCI PharmGKB

  • METHOTREXATE   IKZF1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30044693


    Sources:
    CIViC

  • METHOTREXATE   DROSHA

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24614921


    Sources:
    PharmGKB

  • METHOTREXATE   HLA-E

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   TPM3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8509220


    Sources:
    NCI

  • METHOTREXATE   SLC22A8

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615 21317831


    Sources:
    PharmGKB

  • METHOTREXATE   SLCO1B1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23652803 29683944 28525903 25999454 25098908 24712521 23233662 21317831 19901119 11477075


    Sources:
    CIViC PharmGKB

  • METHOTREXATE   UGT1A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   TAT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1967611


    Sources:
    NCI

  • METHOTREXATE   HSPB2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15519494


    Sources:
    NCI

  • METHOTREXATE   UGT1A7

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   ABCC4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12036927 25502615 25348617 23222202


    Sources:
    NCI PharmGKB

  • METHOTREXATE   UGT1A10

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   LINC00251

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • METHOTREXATE   FOLR1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21317831


    Sources:
    PharmGKB

  • METHOTREXATE   BMP7

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • METHOTREXATE   DOK5

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • METHOTREXATE   CCND1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16870553 12972956


    Sources:
    NCI PharmGKB

  • METHOTREXATE   NOS3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 19671875


    Sources:
    PharmGKB

  • METHOTREXATE   ADA

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2431676


    Sources:
    NCI

  • METHOTREXATE   TLR4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20136356


    Sources:
    PharmGKB

  • METHOTREXATE   KCNA1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10727107


    Sources:
    NCI

  • METHOTREXATE   UGT1A8

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   ABCC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011 27217051 25502615 24241962 23222202 23069858 21317831 18381794


    Sources:
    PharmGKB

  • METHOTREXATE   HLA-C

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28444425


    Sources:
    PharmGKB

  • METHOTREXATE   HGF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10732770


    Sources:
    NCI

  • METHOTREXATE   CDKN1B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14512390


    Sources:
    NCI

  • METHOTREXATE   AFP

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2581382


    Sources:
    NCI

  • METHOTREXATE   ABCC3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22016816 21606946 21317831


    Sources:
    PharmGKB

  • METHOTREXATE   GATA3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • METHOTREXATE   UGT1A6

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   UGT1A3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   UGT1A4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   ABCG2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011 27217051 25778468 21317831 20386493 18256692 18237272


    Sources:
    PharmGKB

  • METHOTREXATE   E2F1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14654896


    Sources:
    NCI

  • METHOTREXATE   UGT1A9

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   NOTCH1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Methotrexate
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type decreased response

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • METHOTREXATE   NCOA3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   FCGR3B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9811059


    Sources:
    NCI

  • METHOTREXATE   SLCO1B3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21317831


    Sources:
    PharmGKB

  • METHOTREXATE   ABCC1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29743634 26086825 21317831 18256692


    Sources:
    PharmGKB

  • METHOTREXATE   GSTM1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17180579


    Sources:
    NCI

  • METHOTREXATE   ADORA2A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27399166 18539621


    Sources:
    PharmGKB

  • METHOTREXATE   RB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Methotrexate
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type decreased response

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • METHOTREXATE   SLC19A1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METHOTREXATE   TYMS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23652803 24284432


    Sources:
    CIViC

  • METHOTREXATE   ALOX5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8151588


    Sources:
    NCI

  • METHOTREXATE   FGFR4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16822847


    Sources:
    PharmGKB

  • METHOTREXATE   IL2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9669212


    Sources:
    NCI

  • METHOTREXATE   BIRC5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15670151


    Sources:
    NCI

  • METHOTREXATE   UGT1A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • METHOTREXATE   BAX

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11237386


    Sources:
    NCI

  • METHOTREXATE   NTRK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8509220


    Sources:
    NCI

  • METHOTREXATE   GLS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15511236


    Sources:
    NCI

  • METHOTREXATE   FLT3

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin
    Indication/Tumor Type acute promyelocytic leukemia
    Response Type sensitive

    PMIDs:
    27626069


    Sources:
    JAX-CKB

  • METHOTREXATE   NR3C1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12210990


    Sources:
    NCI

  • METHOTREXATE   TARDBP

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   MPHOSPH8

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   PPARG

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17363498


    Sources:
    DTC CIViC

  • METHOTREXATE   POLH

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   APEX1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   POLB

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METHOTREXATE   POLI

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METHOTREXATE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METHOTREXATE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METHOTREXATE   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   HSD17B10

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • METHOTREXATE   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHOTREXATE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TdgClinicalTrial: METHOTREXATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications DMARD
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • NCI: METHOTREXATE

    • Version: 14-September-2017

    Alternate Names:
    C642 NCI drug code

    Drug Info:

    Publications:
    Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
    Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.
    Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer

  • NCI: MTX

    • Version: 14-September-2017

    Alternate Names:
    C642 NCI drug code

    Drug Info:

    Publications:
    Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.
    Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.
    Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.

  • NCI: AMETHOPTERIN

    • Version: 14-September-2017

    Alternate Names:
    C642 NCI drug code

    Drug Info:

    Publications:
    Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry

  • DTC: METHOTREXATE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL34259 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • JAX-CKB: Methotrexate

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

  • PharmGKB: methotrexate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer
    Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

  • CIViC: METHOTREXATE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol
    Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood

  • TTD: Methotrexate

    • Version: 2020.06.01

    Alternate Names:
    D0SV8E TTD Drug ID

    Drug Info:

    Publications:

  • DTC: TCMDC-125488

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL426 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL34259

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL34259

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21